drugset / Trial / NCT03222453
Thalassemia Treatment Based on the Stem Cell Technology
Unknown
2 enrolled
Xiaofang Sun
Guangzhou Institutes of Biomedicine and Health Chinese Academy of Sciences · collabNanfang Hospital, Southern Medical University · collabThird Affiliated Hospital, Sun Yat-Sen University · collab
Non-randomizedParallel-groupSingle-blindTreatment
Summary
In order to study the transplantation effect of hematopoetic stem cells from beta-thalassemia induced pluripotent stem cells. We applied clinical grade source of autologous hematopoietic stem cell for the treatment of beta-thalassemia patients, detecting the homing of hematopoietic stem cell transplantation, the differentiation of hematopoietic stem cells in vivo and the hemoglobin beta-chain (HBB) protein expression in the body of recovery, etc., as well as to make a research on the efficacy and safety of hematopoietic stem cells from beta-thalassemia induced pluripotent stem cells.
Timeline
- Start
- 2015-01-01
- Primary completion
- 2016-06-14
- Completion
- 2017-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Hematopoetic stem cells | Unknown | — | — |